Zoll X Series Defibrillator/Pacemaker/Monitor Product Usage: The product is used by qualified...
FDA Device Recall #Z-2401-2012 — Class II — August 16, 2012
Recall Summary
| Recall Number | Z-2401-2012 |
| Classification | Class II — Moderate risk |
| Date Initiated | August 16, 2012 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | ZOLL Medical Corporation |
| Location | Chelmsford, MA |
| Product Type | Devices |
| Quantity | 11 units |
Product Description
Zoll X Series Defibrillator/Pacemaker/Monitor Product Usage: The product is used by qualified medical personnel for the purpose of converting ventricular fibrillation to sinus rhythm or other cardiac rhythms capable of producing hemodynamically significant heart beats. In addition, the product may be used in synchronized mode to terminate certain atrial and ventricular tachycardias and other arrhythmias resistant to drug therapy. The X Series may be used for cardiac pacing in conscious or unconscious patients for up to a few hours duration as an alternative to endocardial stimulation. The X Series may be used for the monitoring a patients electrocardiogram (ECG).
Reason for Recall
Shipped with incorrect software
Distribution Pattern
Worldwide Distribution - US Nationwide including the states of: LA, MA, ME, NC, ND, NE, OH and the country of Germany.
Lot / Code Information
Serial Numbers: AR11J000164, AR12E000853, AR12E000856, AR12E000868, AR12E000920, AR12E000922, AR12E000923, AR12E000931, AR12E000944 AR12F001100, AR12F001298,
Other Recalls from ZOLL Medical Corporation
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-1317-2025 | Class II | Brand Name: ZOLL Product Name: Powerheart G5 A... | Feb 13, 2025 |
| Z-1316-2025 | Class II | Brand Name: ZOLL Product Name: Powerheart G5 A... | Feb 13, 2025 |
| Z-1319-2025 | Class II | Brand Name: ZOLL Product Name: Powerheart G5 A... | Feb 13, 2025 |
| Z-1318-2025 | Class II | Brand Name: ZOLL Product Name: Powerheart G5 A... | Feb 13, 2025 |
| Z-1321-2025 | Class II | Brand Name: ZOLL Product Name: Powerheart G5 A... | Feb 13, 2025 |
Frequently Asked Questions
A software recall means the device's embedded software or firmware has a defect that could affect its performance or safety. Many software recalls are corrected through firmware updates that can be applied without physically replacing the device. For implantable devices, the update may be delivered wirelessly during a routine clinic visit. For external devices, the manufacturer may provide updated software files or replacement units. Contact your healthcare provider to determine whether your specific device and software version are affected and what action is recommended.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.